Decreasing Grade 3/4 Infections, Limited Hospitalizations Underscore Potential for Linvoseltamab in R/R Myeloma
Sundar Jagannath, MBBS, discusses linvoseltamab and expands on key efficacy and safety findings from the LINKER-MM1 trial in patients with relapsed/refractory multiple myeloma.